Literature DB >> 31211243

Beyond growth signaling: apoptotic sensor MERTK activates AKT by a novel mechanism.

Yanqiong Zhang1,2, H Shelton Earp1,3, Pengda Liu1,2.   

Abstract

Canonically the oncogenic kinase AKT is activated by growth signals. Our work suggests apoptotic materials, abundant in tumors, also contribute to AKT activation by stimulating MERTK that in turn phosphorylates Y26 in the AKT PH domain. pY26 reverses binding of an AKT endogenous, WW-domain containing inhibitor, SAV1, allowing AKT responsiveness to classic growth signals. This novel mechanism may contribute to drug resistance.

Entities:  

Keywords:  Akt; Kidney cancer; MERTK; SAV1; drug resistance

Year:  2019        PMID： 31211243      PMCID： PMC6548477          DOI： 10.1080/23723556.2019.1611161

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response.

Authors:  Eric Ubil; Laura Caskey; Alisha Holtzhausen; Debra Hunter; Charlotte Story; H Shelton Earp
Journal:  J Clin Invest       Date:  2018-04-30       Impact factor: 14.808

Review 2.  The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.

Authors:  Douglas K Graham; Deborah DeRyckere; Kurtis D Davies; H Shelton Earp
Journal:  Nat Rev Cancer       Date:  2014-12       Impact factor: 60.716

3.  Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction.

Authors:  Gaetano Zizzo; Brendan A Hilliard; Marc Monestier; Philip L Cohen
Journal:  J Immunol       Date:  2012-08-31       Impact factor: 5.422

Review 4.  The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update.

Authors:  Craig W Lindsley
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

5.  UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.

Authors:  Weihe Zhang; Deborah DeRyckere; Debra Hunter; Jing Liu; Michael A Stashko; Katherine A Minson; Christopher T Cummings; Minjung Lee; Trevor G Glaros; Dianne L Newton; Susan Sather; Dehui Zhang; Dmitri Kireev; William P Janzen; H Shelton Earp; Douglas K Graham; Stephen V Frye; Xiaodong Wang
Journal:  J Med Chem       Date:  2014-08-06       Impact factor: 7.446

6.  The long noncoding RNA HOTAIR activates the Hippo pathway by directly binding to SAV1 in renal cell carcinoma.

Authors:  Guanghui Hu; Binbin Dong; Jingwei Zhang; Wei Zhai; Tiancheng Xie; Bisheng Huang; Chi Huang; Xudong Yao; Junhua Zheng; Jianping Che; Yun-Fei Xu
Journal:  Oncotarget       Date:  2017-04-25

7.  Suppression of insulin feedback enhances the efficacy of PI3K inhibitors.

Authors:  Benjamin D Hopkins; Chantal Pauli; Xing Du; Diana G Wang; Xiang Li; David Wu; Solomon C Amadiume; Marcus D Goncalves; Cindy Hodakoski; Mark R Lundquist; Rohan Bareja; Yan Ma; Emily M Harris; Andrea Sboner; Himisha Beltran; Mark A Rubin; Siddhartha Mukherjee; Lewis C Cantley
Journal:  Nature       Date:  2018-07-04       Impact factor: 49.962

8.  Protein Phosphatase 1 Regulatory Subunit SDS22 Inhibits Breast Cancer Cell Tumorigenesis by Functioning as a Negative Regulator of the AKT Signaling Pathway.

Authors:  Debasish Paul; Anil Bapu Bargale; Srikanth Rapole; Praveen Kumar Shetty; Manas Kumar Santra
Journal:  Neoplasia       Date:  2018-11-27       Impact factor: 5.715

9.  MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression.

Authors:  Yao Jiang; Yanqiong Zhang; Janet Y Leung; Cheng Fan; Konstantin I Popov; Siyuan Su; Jiayi Qian; Xiaodong Wang; Alisha Holtzhausen; Eric Ubil; Yang Xiang; Ian Davis; Nikolay V Dokholyan; Gang Wu; Charles M Perou; William Y Kim; H Shelton Earp; Pengda Liu
Journal:  Nat Commun       Date:  2019-04-03       Impact factor: 14.919

10.  The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.

Authors:  Christopher J Ricketts; Aguirre A De Cubas; Huihui Fan; Christof C Smith; Martin Lang; Ed Reznik; Reanne Bowlby; Ewan A Gibb; Rehan Akbani; Rameen Beroukhim; Donald P Bottaro; Toni K Choueiri; Richard A Gibbs; Andrew K Godwin; Scott Haake; A Ari Hakimi; Elizabeth P Henske; James J Hsieh; Thai H Ho; Rupa S Kanchi; Bhavani Krishnan; David J Kwiatkowski; Wembin Lui; Maria J Merino; Gordon B Mills; Jerome Myers; Michael L Nickerson; Victor E Reuter; Laura S Schmidt; C Simon Shelley; Hui Shen; Brian Shuch; Sabina Signoretti; Ramaprasad Srinivasan; Pheroze Tamboli; George Thomas; Benjamin G Vincent; Cathy D Vocke; David A Wheeler; Lixing Yang; William Y Kim; A Gordon Robertson; Paul T Spellman; W Kimryn Rathmell; W Marston Linehan
Journal:  Cell Rep       Date:  2018-04-03       Impact factor: 9.423
  10 in total
  1 in total

1.  Correction of the tumor suppressor Salvador homolog-1 deficiency in tumors by lycorine as a new strategy in lung cancer therapy.

Authors:  Zhe Zhao; Shufen Xiang; Jindan Qi; Yijun Wei; Mengli Zhang; Jun Yao; Tong Zhang; Mei Meng; Xiaohua Wang; Quansheng Zhou
Journal:  Cell Death Dis       Date:  2020-05-21       Impact factor: 8.469
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.